A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy
Status:
Completed
Trial end date:
2020-08-05
Target enrollment:
Participant gender:
Summary
This is a randomized, parallel-arm, multicenter study to compare the safety and efficacy
profiles of SEL-212 and KRYSTEXXA®. Patients will be randomized 1:1 to receive treatment with
SEL-212 or KRYSTEXXA® for 6 months. Efficacy assessments, as measured by serum uric acid
(SUA) levels, will be conducted at intervals that are appropriate to determine treatment
effect differences. Safety will be monitored throughout the study.